Long-term safety and tolerability of frespaciguat: the INSIGNIA-PAH extension
<title>Extract</title> Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease requiring long-term management to prevent right ventricular failure and improve outcomes [1, 2]. Despite advancements in PAH vasodilator therapies targeting the endothelin, prostacyclin, and nitric oxide pathways, systemic side effects remain a challenge that often limit optimal dosing, particularly with use of combination regimens [3]. While inhaled options exist, frequent administration and systemic side effects pose challenges [4, 5].
Authors
- Marius M. Hoeper (ORCID: https://orcid.org/0000-0001-9086-2293)
- Paul M. Hassoun (ORCID: https://orcid.org/0000-0003-0601-4975)
- María José Loureiro (ORCID: https://orcid.org/0000-0002-5430-5585)
- Humberto García‐Aguilar (ORCID: https://orcid.org/0000-0002-2519-0096)
- Wei Fu (ORCID: https://orcid.org/0009-0006-0365-7704)
- Guillermo Bortman (ORCID: https://orcid.org/0000-0003-4437-6854)
- Carmen La Rosa
- Pei Niu (ORCID: https://orcid.org/0000-0002-3738-404X)
- Mackenzie A. Ford
- Kelly Chin (ORCID: https://orcid.org/0000-0002-1214-6723)
- Marc Humbert (ORCID: https://orcid.org/0000-0003-0703-2892)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Johns Hopkins University (US)
- Inserm (FR)
- Université Paris-Saclay (FR)
- Johns Hopkins Medicine (US)
- Medizinische Hochschule Hannover (DE)
- Marienhospital Stuttgart (DE)
- Merck Institute for Science Education (US)
- Hospital de Niños de la Santísima Trinidad (AR)
- Hospital del Niño (PA)
- Bicêtre Hospital (FR)
- University of Baltimore (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1183/13993003.01459-2025
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00